Cargando…
Response of fibroblast growth factor 23 to volume interventions in arterial hypertension and diabetic nephropathy
Fibroblast growth factor 23 (FGF-23) rises progressively in chronic kidney disease and is associated with adverse cardiovascular outcomes. FGF-23 putatively induces volume retention by upregulating the sodium-chloride cotransporter (NCC). We studied whether, conversely, interventions in volume statu...
Autores principales: | Humalda, Jelmer K., Seiler-Mußler, Sarah, Kwakernaak, Arjan J., Vervloet, Marc G., Navis, Gerjan, Fliser, Danilo, Heine, Gunnar H., de Borst, Martin H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5120892/ https://www.ncbi.nlm.nih.gov/pubmed/27861335 http://dx.doi.org/10.1097/MD.0000000000005003 |
Ejemplares similares
-
Dietary sodium restriction: a neglected therapeutic opportunity in chronic kidney disease
por: Humalda, Jelmer K., et al.
Publicado: (2014) -
Hypertension/prehypertension and its determinants in pediatric IgA nephropathy
por: Fu, Qing-Ying, et al.
Publicado: (2020) -
High Fibroblast Growth Factor 23 Levels Associated With Low Hemoglobin Levels in Patients With Chronic Kidney Disease Stages 3 and 4
por: Tsai, Ming-Hsien, et al.
Publicado: (2016) -
Associations of serum soluble klotho and fibroblast growth factor 23 with carotid artery calcification in patients undergoing continuous ambulatory peritoneal dialysis: A retrospective study
por: Guo, Naifeng, et al.
Publicado: (2021) -
IgA nephropathy pathogenesis and therapy: Review & updates
por: Habas, Elmukhtar, et al.
Publicado: (2022)